Background: Parkinson's disease is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra. Long-term L-Dopa therapy is associated with the development of motor complications that reduce patients' quality of life. Safinamide is a selective reversible MAO-B inhibitor with an additional mechanism of glutamate release modulation, d…